ClinicalTrials.gg
CompletedNCT04911361Updated Jan 3, 2022

The DEPOT Study (Dry Eye Prescription Options for Therapy)

A Phase 4 interventional study of Dexamethasone in Dry Eye, sponsored by Research Insight LLC. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-03.

Sponsored by Research Insight LLC · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2021, 4 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing dexamethasone in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. Dexamethasone · Dry Eye Syndromes.

Enrollment
5th of 16
50 · median 36
Started
2021
with 4 others
Phase 4
12 of 16
none open now
Registered
15th of 16
by date
Lead sponsor
1 of 16
Research Insight LLC

Among the 16 studies testing dexamethasone in Dry Eye Syndromes, this one is the 5th largest by enrollment, is one of 5 that started in 2021, is one of 12 in phase 4, and was the 15th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

None of the 16 studies testing dexamethasone in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →

Where they have run

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing dexamethasone in Dry Eye Syndromes as a file.
02

Study summary

Assessing DEXTENZA efficacy and safety when placed within the lower eyelid canaliculus for dry eye flares in comparison to topical loteprednol suspension.

Read the detailed description

The DEPOT Study (Dry Eye Prescription Options for Therapy): A randomized controlled clinical trial assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg insert, when placed within the lower eye eyelid canaliculus in comparison to topical loteprednol suspension for the treatment of episodic dry eye.

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 years and older
  • Patients willing to take an electronic survey about their tolerability of either study medication.
  • Patients with a recent exacerbation of dry eye characterized by ocular surface discomfort.

Exclusion criteria

Exclusion Criteria:

  • Active, systemic or local disease condition other than DES that causes ocular surface irritation that could interfere with the evaluation and treatment of dry eye.
  • Any of the following ocular (eye or eyelid) conditions in either eye within 1 Months prior to the enrollment visit:

    • Ocular surgery (e.g., intraocular, oculoplastic, corneal or refractive surgery procedure)
    • Clinically significant ocular trauma.
    • Active ocular Herpes simplex or Herpes zoster (eye or eyelid) infection.
    • Ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis)
    • Ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including hordeolum/stye)
  • Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis
  • Eyelid abnormalities that significantly affect lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis)
  • Ocular surface abnormality that may compromise corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, or map dot fingerprint dystrophy)
  • Participation in another ophthalmic clinical trial involving a therapeutic drug or device within 30 days prior to the distribution of the survey
  • Participation in this trial in the same patient's fellow eye.
  • Patients who are pregnant or breastfeeding or who may become pregnant during participation in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    Topical loteprednol suspension in both eyes

    25 subjects will be randomized to receive treatment loteprednol etabonate 0.5% suspension QID for 2 weeks.

    Drug: Dexamethasone

  • Experimental
    Lower eyelid canaliculi DEXTENZA insertion (study group)

    25 subjects will be randomized to receive treatment of OTX-DED

    Drug: Dexamethasone

Interventions

  • Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)

    Also known as: DEXTENZA

06

What researchers measure

Primary outcomes

  1. To determine effect of dexamethasone insert

    SPEED score at Baseline and Week 2

    Time frame: 2 Weeks

Secondary outcomes

  1. To determine the effect of dexamethasone insert

    The difference in SPEED questionnaire scores before and 4 weeks after treatment.

    Time frame: 4 Weeks

  2. The difference in conjunctival hyperemia

    Slit exam to determine ocular hyperemia using the Schulze Scale before and 4 weeks after treatment

    Time frame: 4 weeks

  3. The difference in tear break up time (TBUT) before and after treatment

    Reduced tear break up time (TBUT) ≤ 10 seconds

    Time frame: 4 Weeks

  4. The difference in corneal staining before and after treament

    The presence of central or inferior staining defined by the Oxford Scale

    Time frame: 4 Weeks

Other outcomes

  1. Safety outcome measure

    Intraocular pressure at Baseline, Week 2 \& 4

    Time frame: At baseline, 2 weeks, and 4 weeks

07

Study locations

3 sites
  • Inland Eye Specialists
    Hemet, California 92545, United States
  • Harvard Eye Associates
    Laguna Hills, California 92653, United States
  • Ophthalmology Associates
    Saint Louis, Missouri 63131, United States
08

References and documents

Publications

  • Tyson SL, Bafna S, Gira JP, Goldberg DF, Jones JJ, Jones MP, Kim JK, Martel JM, Nordlund ML, Piovanetti-Perez IK, Singh IP, Metzinger JL, Mulani D, Sane S, Talamo JH, Goldstein MH; Dextenza Study Group. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2019 Feb;45(2):204-212. doi: 10.1016/j.jcrs.2018.09.023. Epub 2018 Oct 24. Erratum In: J Cataract Refract Surg. 2019 Jun;45(6):895. doi: 10.1016/j.jcrs.2019.05.003. PubMed 30367938 ↗
  • Walters TR, et al. Efficacy and Safety of Sustained Release Dexamethasone for the Treatment of Ocular Pain and Inflammation after Cataract Surgery: Results from Two Phase 3 Studies. J Clin Exp Ophthalmol. 2016; 7(4):

Individual participant data

Plan to share: Yes — IPD results will be shared in publication.

Supporting information: Study protocol

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Dec 2021, 4 months.

Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 4 months is below that.

Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2021
First posted
Jun 3, 2021
StartActual
Aug 10, 2021
Primary completionActual
Dec 28, 2021
CompletionActual
Dec 28, 2021
Last update
Jan 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04911361
Lead sponsor
Research Insight LLC
Responsible party
Sponsor
First posted
Jun 3, 2021
Start date
Aug 10, 2021
Primary completion
Dec 28, 2021
Completion
Dec 28, 2021
Last update
Jan 3, 2022

Study contacts

John Hovanesian, MD
principal investigator · Research Insight LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion